Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 241 to 250 of 1113 total matches.

In Brief: New Benzodiazepine Warnings

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020  (Issue 1610)
controlled substances. Postmarketing data and published literature have shown an increasing rate ...
The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine labels have contained a boxed warning about a risk of serious drug interactions with opioids since 2016.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):175 |  Show IntroductionHide Introduction

In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million ...
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
Med Lett Drugs Ther. 2021 May 3;63(1623):e1 |  Show IntroductionHide Introduction

COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
are no longer authorized for use as booster doses in any age group.1 No data on use of the bivalent vaccines ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e1 |  Show IntroductionHide Introduction

Fluconazole

   
The Medical Letter on Drugs and Therapeutics • May 18, 1990  (Issue 818)
esophageal candidiasis, but the clinical response was faster with fluconazole. Available data are inadequate ...
Fluconazole (Diflucan - Roerig), an antifungal azole, was recently approved by the US Food and Drug Administration for oral and intravenous (IV) treatment of cryptococcal meningitis and various forms of candidiasis. Both cryptococcal meningitis and candidiasis occur frequently in patients with AIDS, organ transplants, or cancer.
Med Lett Drugs Ther. 1990 May 18;32(818):50-2 |  Show IntroductionHide Introduction

A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 1999  (Issue 1065)
’ treatment with the most prescribed tablet size, based on data from retail pharmacies nationwide provided ...
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Med Lett Drugs Ther. 1999 Nov 5;41(1065):105-6 |  Show IntroductionHide Introduction

Linezolid (Zyvox)

   
The Medical Letter on Drugs and Therapeutics • May 29, 2000  (Issue 1079)
of 10. No published data are available on the effectiveness of linezolid in pneumonia caused ...
Linezolid, the first of a new class of antibiotics, the oxazolidinones, has been marketed for treatment of infection due to vancomycin-resistant Enterococcus faecium, nosocomial and community-acquired pueumonia due to Staphylococcus aureus or penicillin-sucsceptible Streptococcus pneumoniae, and skin and skin structure infections, including those due to methicillin-resistant S. aureus (MRSA).
Med Lett Drugs Ther. 2000 May 29;42(1079):45-6 |  Show IntroductionHide Introduction

Gleevec (STI-571) For Chronic Myeloid Leukemia

   
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001  (Issue 1106)
hours. No data are available on use of imatinib in patients with hepatic or renal impairment. CLINICAL ...
Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.
Med Lett Drugs Ther. 2001 Jun 11;43(1106):49-50 |  Show IntroductionHide Introduction

Adalimumab (Humira) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2003  (Issue 1153)
traditional DMARDs. PHARMACOKINETICS — According to the manufacturer’s data, the absolute bioavailability ...
Adalimumab (Humira - Abbott), a tumor necrosis factor alpha (TNF-α) inhibitor, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA). A genetically engineered human IgG1 monoclonal antibody, adalimumab is approved for subcutaneous (SC) injection in adults who have failed at least one disease-modifying anti-rheumatic drug (DMARD), for use either alone or with other DMARDs such as methotrexate (Rheumatrex, and others). Two other TNF-α antagonists, etanercept (Enbrel) and infliximab (Remicade), are already on the market for treatment of RA (Treatment...
Med Lett Drugs Ther. 2003 Mar 31;45(1153):25-7 |  Show IntroductionHide Introduction

Two Once-Daily Fixed-Dose NRTI Combinations for HIV

   
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005  (Issue 1203)
days’ treatment, according to the most recent data (January 31, 2005) from retail pharmacies nationwide ...
The FDA has approved emtricitabine/tenofovir (Truvada - Gilead) and abacavir/lamivudine (Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for once-daily use in treatment of HIV infection. Two other fixed-dose NRTI combinations were previously approved for twice-daily dosing. Dual NRTI therapy is generally used in either an NNRTI (non-nucleoside reverse transcriptase inhibitor)-based or a PI (protease inhibitor)-based regimen.
Med Lett Drugs Ther. 2005 Feb 28;47(1203):19-20 |  Show IntroductionHide Introduction

ARBs and Myocardial Infarction

   
The Medical Letter on Drugs and Therapeutics • May 09, 2005  (Issue 1208)
’ treatment based on lowest usual daily dosage, according to most recent data (March 31, 2005) from retail ...
Angiotensin receptor blockers (ARBs) are widely used as an alternative to angiotensin converting enzyme (ACE) inhibitors for treatment of hypertension because they lower blood pressure without inducing a cough. It has not been established that they provide the same cardiac benefits as ACE inhibitors. Recently, an editorial in the British Medical Journal suggested that ARBs may increase the risk of myocardial infarction.
Med Lett Drugs Ther. 2005 May 9;47(1208):38-9 |  Show IntroductionHide Introduction